Full Text Journal Articles by
Author Ayako Urabe

Advertisement

Find full text journal articles








Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study.

Hideharu Okanobu, Tomohiko Kohno, Ritsuo Mouri, Yoshiki Hatsushika, Yumiko Yamashita, Eisuke Miyaki, Takayuki Fukuhara, Akihito Okazaki, Ayaka Sakano, Ayako Urabe, Shintaro Takaki, Nami Mori, Keiji Tsuji, Hidenori Ochi, Yoshinari Furukawa,

<h4>Background</h4>The study aimed to investigate the efficacy of vonoprazan 10 mg compared with 20 mg in patients with erosive esophagitis.<h4>Method</h4>Seventy-three patients with erosive esophagitis were randomly divided into two groups either vonoprazan 20 mg (n = 37) or 10 mg (n = 36). They were administered each dose for 4 weeks as the initial treatment followed by maintenance treatment ... Read more >>

Esophagus (Esophagus : official journal of the Japan Esophageal Society)
[2021, 18(3):669-675]

Cited: 1 time

View full text PDF listing >>



Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.

Tadashi Kegasawa, Ryotaro Sakamori, Kazuki Maesaka, Ryoko Yamada, Yuki Tahata, Ayako Urabe, Takahiro Kodama, Hayato Hikita, Kazuho Imanaka, Kazuyoshi Ohkawa, Naoki Hiramatsu, Masahide Oshita, Yukinori Yamada, Masami Inada, Takayuki Yakushijin, Yasuharu Imai, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background and aim</h4>Although the serum sodium level has been reported to be a prognostic and predictive marker for the therapeutic effects of lung cancer and renal cell carcinoma treated with molecular targeted therapy, the serum sodium level has not been investigated in hepatocellular carcinoma (HCC) patients treated with sorafenib. The ... Read more >>

Dig Dis Sci (Digestive diseases and sciences)
[2021, 66(5):1720-1729]

Cited: 0 times

View full text PDF listing >>



Advertisement

Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment.

Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Ryoko Yamada, Kazuyoshi Ohkawa, Naoki Hiramatsu, Hideki Hagiwara, Masahide Oshita, Yasuharu Imai, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>It remains unclear how direct-acting antiviral (DAA) treatments influence hepatocellular carcinoma (HCC) recurrence and survival in comparison with interferon (IFN).<h4>Methods</h4>In total, 338 patients with chronic hepatitis C virus (HCV) infection and previous HCC treatments who initiated IFN (N = 88, IFN group) or DAA treatment (N = 250, DAA group) from January 2005 to ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(10):1118-1127]

Cited: 1 time

View full text PDF listing >>



Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Ayako Urabe, Yuki Tahata, Masahide Oshita, Kazuyoshi Ohkawa, Eiji Mita, Hideki Hagiwara, Shinji Tamura, Toshifumi Ito, Takayuki Yakushijin, Sadaharu Iio, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Preserved liver function may be an important factor affecting therapeutic efficacy in hepatocellular carcinoma patients treated with lenvatinib, but not all patients can be treated while preserving liver function. This study evaluated the therapeutic efficacy of lenvatinib in patients with poor liver function with and without portal hypertension.<h4>Methods</h4>This prospectively registered ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(9):1091-1100]

Cited: 0 times

View full text PDF listing >>



Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.

Naoki Morishita, Ryotaro Sakamori, Tomomi Yamada, Yugo Kai, Yuki Tahata, Ayako Urabe, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Yoshinori Doi, Shinji Tamura, Hideki Hagiwara, Yasuharu Imai, Sadaharu Iio, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Background</h4>L31 and Y93 in the NS5A region of the hepatitis C virus (HCV) are the most important substitution positions associated with resistance to direct-acting antiviral (DAA) treatment.<h4>Methods</h4>We analyzed the frequency of NS5A L31M/V and Y93/H in NS5A inhibitor-naive HCV genotype 1 patients who received asunaprevir plus daclatasvir combination treatment using ... Read more >>

PLoS One (PloS one)
[2020, 15(6):e0234811]

Cited: 0 times

View full text PDF listing >>



Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment.

Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Ryoko Yamada, Kazuyoshi Ohkawa, Naoki Hiramatsu, Hideki Hagiwara, Masahide Oshita, Taizo Hijioka, Shinji Tamura, Yasuharu Imai, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Several studies have recently reported that hepatocellular carcinoma (HCC) occurrence does not differ between hepatitis C virus patients receiving interferon (IFN)-based and IFN-free treatments considering the patients' backgrounds. However, liver fibrosis was not directly considered in these studies.<h4>Methods</h4>In total, 3972 patients without a history of HCC who started IFN-based or IFN-free ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(3):313-320]

Cited: 0 times

View full text PDF listing >>



Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Ayako Urabe, Minoru Shigekawa, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

AIM:Intermediate-stage hepatocellular carcinoma (HCC) targeted for transcatheter arterial chemoembolization (TACE) corresponds to a highly heterogeneous population for whom the factors predicting TACE efficacy have not been established. This study aimed to evaluate the impact of hypovascular hepatic nodules coexisting with intermediate-stage HCC as a significant predictive factor for TACE refractoriness. ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2020, 50(3):365-373]

Cited: 3 times

View full text PDF listing >>



Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients.

Ayako Urabe, Ryotaro Sakamori, Yuki Tahata, Ryoko Yamada, Yasuharu Imai, Hideki Hagiwara, Shinji Tamura, Hiroyuki Fukui, Yukinori Yamada, Akira Kaneko, Taizo Hijioka, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara,

<h4>Aim</h4>Sofosbuvir (SOF) and ribavirin (RBV) combination therapy has improved the sustained virologic response (SVR) rate and shortened the treatment duration for patients with chronic hepatitis C virus (HCV) genotype 2 infection. Ribavirin-induced hemolytic anemia is one of the most troublesome side-effects of SOF/RBV therapy; however, factors associated with this condition ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(8):853-859]

Cited: 0 times

View full text PDF listing >>



Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.

Ryoko Yamada, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Naoki Morishita, Takahiro Kodama, Hayato Hikita, Ryotaro Sakamori, Takayuki Yakushijin, Akira Yamada, Hideki Hagiwara, Eiji Mita, Masahide Oshita, Toshifumi Itoh, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Atsuo Inoue, Yasuharu Imai, Tomohide Tatsumi, Toshimitsu Hamasaki, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment α-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2019, 49(5):570-578]

Cited: 7 times

View full text PDF listing >>



Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.

Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Sadaharu Iio, Akira Yamada, Hideki Hagiwara, Eiji Mita, Yukinori Yamada, Toshifumi Ito, Masami Inada, Kazuhiro Katayama, Iwao Yabuuchi, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

<h4>Aim</h4>Simeprevir (SMV)-based triple therapy is an effective retreatment option following failure of telaprevir (TVR)-based triple therapy. However, it is unclear whether the persistence of resistance-associated variants (RAVs) induced by TVR-based therapy may reduce the treatment effect of SMV-based therapy.<h4>Methods</h4>The factors associated with the treatment effect, including RAVs in the NS3 ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2017, 47(8):773-782]

Cited: 2 times

View full text PDF listing >>



Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C.

Kei Morio, Michio Imamura, Yoshiiku Kawakami, Reona Morio, Masahiro Hatooka, Hiromi Kan, Hatsue Fujino, Takayuki Fukuhara, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Ayako Urabe, Satoe Yokoyama, Yuko Nagaoki, Tomokazu Kawaoka, Nobuhiko Hiraga, Masataka Tsuge, Akira Hiramatsu, C Nelson Hayes, Hiroshi Aikata, Hidenori Ochi, Kazuaki Chayama, ,

<h4>Aim</h4>Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known.<h4>Methods</h4>We analyzed 212 patients with genotype 1 chronic hepatitis C, who were treated with simeprevir plus PEG-IFN/RBV triple therapy, and assessed the ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2016, 46(12):1256-1263]

Cited: 3 times

View full text PDF listing >>



Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.

Yuki Tahata, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yukinori Yamada, Masami Inada, Kazuhiro Katayama, Shinji Tamura, Yasuharu Imai, Hayato Hikita, Ryotaro Sakamori, Yuichi Yoshida, Tomohide Tatsumi, Norio Hayashi, Tetsuo Takehara,

The factors associated with sustained virologic response (SVR) in chronic hepatitis C (CH-C) genotype 1 patients treated with simeprevir (SMV), pegylated interferon (Peg-IFN) plus ribavirin (RBV) triple therapy have not been fully investigated. Two hundred and twenty-nine treatment-naïve CH-C patients treated with SMV triple therapy were enrolled in this study. ... Read more >>

J Med Virol (Journal of medical virology)
[2016, 88(10):1776-1784]

Cited: 1 time

View full text PDF listing >>



Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C.

Yuko Nagaoki, Michio Imamura, Yoshiiku Kawakami, Hiromi Kan, Hatsue Fujino, Takayuki Fukuhara, Tomoki Kobayashi, Atsushi Ono, Takashi Nakahara, Noriaki Naeshiro, Ayako Urabe, Satoe Yokoyama, Daisuke Miyaki, Eisuke Murakami, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Hiroshi Aikata, Shoichi Takahashi, C Nelson Hayes, Hidenori Ochi, Kazuaki Chayama, ,

AIM:The predictive value of the recently identified interferon-λ (IFNL)4 polymorphism on the outcome of telaprevir (TVR), pegylated interferon (PEG IFN) plus ribavirin (RBV) combination therapy for chronic hepatitis C is unknown. METHODS:We assessed predictive factors for sustained virological response (SVR) for TVR, PEG IFN plus RBV combination therapy in 283 ... Read more >>

Hepatol Res (Hepatology research : the official journal of the Japan Society of Hepatology)
[2014, 44(14):E447-54]

Cited: 7 times

View full text PDF listing >>



Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

Hatsue Fujino, Michio Imamura, Yuko Nagaoki, Yoshiiku Kawakami, Hiromi Abe, C Nelson Hayes, Hiromi Kan, Takayuki Fukuhara, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Youji Honda, Noriaki Naeshiro, Ayako Urabe, Satoe Yokoyama, Daisuke Miyaki, Eisuke Murakami, Tomokazu Kawaoka, Nobuhiko Hiraga, Masataka Tsuge, Akira Hiramatsu, Hideyuki Hyogo, Hiroshi Aikata, Shoichi Takahashi, Daiki Miki, Hidenori Ochi, Waka Ohishi, Kazuaki Chayama, ,

<h4>Background</h4>Older patients with chronic hepatitis C have a lower virological response to interferon (IFN) treatment compared to younger patients. The efficacy of telaprevir (TVR) and PEG-IFN plus ribavirin combination therapy and the predictive value of recently identified IFN lambda (IFNL) 4 polymorphisms on the outcome of therapy for older patients ... Read more >>

J Gastroenterol (Journal of gastroenterology)
[2014, 49(12):1548-1556]

Cited: 15 times

View full text PDF listing >>



Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.

Daisuke Miyaki, Hiroshi Aikata, Hiromi Kan, Hatsue Fujino, Ayako Urabe, Keiichi Masaki, Takayuki Fukuhara, Tomoki Kobayashi, Noriaki Naeshiro, Takashi Nakahara, Tomokazu Kawaoka, Akira Hiramatsu, Shoichi Takahashi, Masaki Ishikawa, Hideaki Kakizawa, Kazuo Awai, Kazuaki Chayama,

<h4>Background and aim</h4>It has been reported about poor prognosis in patients with advanced hepatocellular carcinoma (HCC) refractory to hepatic arterial infusion chemotherapy (HAIC). We assessed the survival benefits of sorafenib therapy for advanced HCC in HAIC refractory patients.<h4>Methods</h4>The study subjects were 191 patients with advanced HCC who had been treated ... Read more >>

J Gastroenterol Hepatol (Journal of gastroenterology and hepatology)
[2013, 28(12):1834-1841]

Cited: 11 times

View full text PDF listing >>





Advertisement


Disclaimer

0.9434 s